ACHFF (Arch Biopartners) Beginning Cash Position: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACHFF Arch Biopartners Inc ACHFF
22 GF Score
Price $0.61
! 4 Warning Signs
View Full Analysis

What is Arch Biopartners Beginning Cash Position?

Arch Biopartners ACHFF +0.90% 22 Beginning Cash Position is $0.00 Mil as of Mar. 2026. GuruFocus rates ACHFF with a GF Score™ of 22/100. The stock has 4 warning signs investors should review.

Arch Biopartners's Beginning Cash Position for the quarter that ended in Mar. 2026 was $0.00 Mil.

Arch Biopartners's quarterly Beginning Cash Position declined from Sep. 2025 ($0.12 Mil) to Dec. 2025 ($0.00 Mil) but then increased from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

Arch Biopartners's annual Beginning Cash Position increased from Sep. 2023 ($0.37 Mil) to Sep. 2024 ($0.61 Mil) but then declined from Sep. 2024 ($0.61 Mil) to Sep. 2025 ($0.00 Mil).

Arch Biopartners Beginning Cash Position Related Terms

Arch Biopartners Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Arch Biopartners's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arch Biopartners Beginning Cash Position Chart

Arch Biopartners Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.52 0.34 0.37 0.61 0.00

Arch Biopartners Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.01 0.12 0.00 0.00
ACHFF
22GF Score
Arch Biopartners Inc ACHFF
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arch Biopartners Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $0.00 Mil mean?
Arch Biopartners (ACHFF) has a Beginning Cash Position of $0.00 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Arch Biopartners and its competitors.
Is Arch Biopartners' Beginning Cash Position too high?
Arch Biopartners' current Beginning Cash Position is $0.00 Mil. Overall, Arch Biopartners has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Arch Biopartners' Beginning Cash Position compare to VRTX and REGN?
Arch Biopartners' Beginning Cash Position of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Arch Biopartners and its competitors. Arch Biopartners's current Beginning Cash Position is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arch Biopartners stock overvalued right now?
Arch Biopartners (ACHFF) has a current Beginning Cash Position of $0.00 Mil. The current Beginning Cash Position is $0.00 Mil. Arch Biopartners' overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Arch Biopartners (ACHFF), the current Beginning Cash Position is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arch Biopartners Business Description

Other Exchanges 8HA:GermanyARCH:Canada
Address 545 King Street West, Toronto, ON, CAN, M5V 1M1
Arch Biopartners Inc is a developer of a therapeutic pipeline designed to address acute kidney injury (AKI) and chronic kidney disease (CKD) by targeting inflammation- and toxin-related kidney damage. The group offers mechanism-based treatments, enabling patients suffering from both acute and chronic kidney conditions to benefit from novel, targeted therapies that address unmet medical needs in kidney care.
22GF Score

Get the complete analysis for ACHFF

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.61
Price